EGFR and non-small cell lung carcinoma: In conclusion, the efficacy outcomes improved by adjuvant osimertinib in the ADAURA trial and offered to patients with resected EGFR-mutated stage IB-IIIA NSCLC are a statistically but also clinically significant prolongation of disease-free survival and overall survival.